Labcorp named to Fortune® Magazine’s 2022 ‘World’s Most Admired Companies’ list for the fourth time

BURLINGTON, N.C. --(BUSINESS WIRE)--Feb. 2, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, has been named to FORTUNE® magazine's 2022 list of the World’s Most Admired Companies, marking its fourth appearance on the list. The annual survey, conducted by FORTUNE and Korn Ferry, a global organizational consulting firm, asks top executives, directors and financial analysts to identify the companies with the strongest reputations across various industries.

Labcorp earns 100% on Human Rights Campaign Foundation’s annual scorecard on LGBTQ+ Workplace Equality

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 27, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it received a perfect score of 100% on the Human Rights Campaign Foundation’s 2022 Corporate Equality Index (CEI), the nation’s foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ+ workplace equality.

Siemens Healthineers launches Enhanced Liver Fibrosis (ELF) test in the U.S.

TARRYTOWN, N.Y., Jan. 26, 2022 —The Enhanced Liver Fibrosis (ELF) Test from Siemens Healthineers is now available in the United States, providing broad clinical access to the minimally invasive prognostic tool. Currently, the ELF Test is exclusively available through collaborations with Labcorp (NYSE: LH) and Quest Diagnostics (NYSE: DGX), providing access (with a physician’s order) across the country. This is the first time the test is commercially available in the U.S., following De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) in August 2021.

Labcorp to offer risk-scoring test for people with advanced liver fibrosis due to NASH

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 26, 2022-- For the millions of people in the United States living with an advanced form of chronic liver disease, simply understanding the potential for future complications could help stave off severe damage and even a transplant. Labcorp (NYSE: LH), a leading global life sciences company, is making this possible by offering the Enhanced Liver Fibrosis (ELF™) test. Developed by Siemens Healthineers, the physician-ordered blood test helps assess the risk of disease progression in individuals—opening the door for improved outcomes. The test has been granted De Novo marketing authorization by the U.S. Food and Drug Administration .